Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression
NCT06667700Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2024
- Primary completion
- Jan 2031
- Modality
- RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 24
01
Overview
A Phase 3 trial of molnupiravir in coronavirus disease 2019 (COVID-19), sponsored by Merck & Co.. Started Dec 2024; status: recruiting.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06667700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667700.